Blood cancer & rare hematologic therapies, organized by condition.

A bispecific CD19/CD3 T-cell engager for infants, children and adults with CD19-positive B-cell precursor acute lymphoblastic leukemia.

Used to treat adults and children with hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome.

A T-cell costimulation modulator for severe rheumatoid arthritis and moderate-to-severe polyarticular juvenile idiopathic arthritis.

An oral kinase inhibitor for intermediate or high-risk myelofibrosis, including forms linked to prior polycythemia vera or essential thrombocythemia, in patients with anemia.

A bispecific CD20/CD3 T-cell engager for relapsed or refractory large B-cell lymphoma after two or more prior treatment lines.

A CD19-directed antibody combined with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.

A CD19-targeted antibody-drug conjugate for relapsed or refractory large B-cell lymphoma after two or more prior therapies.

A bispecific GPRC5D/CD3 T-cell engager for heavily pretreated relapsed or refractory multiple myeloma.

An immunostimulatory antibody combined with lenalidomide and dexamethasone for multiple myeloma after one to three prior therapies.

An oral proteasome inhibitor combined with lenalidomide and dexamethasone for multiple myeloma after at least one prior therapy.

A nuclear export inhibitor combined with dexamethasone for relapsed or refractory multiple myeloma.

A BCMA-directed antibody-drug conjugate for relapsed or refractory multiple myeloma after prior treatment.

A bispecific BCMA/CD3 T-cell engager for multiple myeloma that has relapsed after at least four prior therapy lines.

An IDH2 inhibitor for relapsed or refractory acute myeloid leukemia carrying an IDH2 mutation.

A menin inhibitor for relapsed or refractory acute myeloid leukemia with an NPM1 mutation and no satisfactory alternative options.

Treats skin symptoms of cutaneous T-cell lymphoma that has progressed after two prior systemic therapies.

A menin inhibitor for relapsed or refractory acute leukemia carrying a KMT2A gene translocation, in adult and pediatric patients.

A histone deacetylase inhibitor for relapsed or refractory peripheral T-cell lymphoma.

A folate-pathway inhibitor for relapsed or refractory peripheral T-cell lymphoma.

A small interfering RNA therapy given for routine prophylaxis to prevent or reduce bleeding episodes.

A complement factor D inhibitor added to ravulizumab or eculizumab therapy for extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.

An oral kinase inhibitor for symptomatic tenosynovial giant cell tumor when surgery isn't a good option.

A CD33-directed antibody-drug conjugate for newly diagnosed or relapsed/refractory CD33-positive acute myeloid leukemia.

A liposomal combination chemotherapy for certain therapy-related or MDS-related acute myeloid leukemia.

An asparagine-depleting enzyme used for ALL patients who've developed hypersensitivity to E. coli-derived asparaginase.